structure conference like enhancing for start year a developments. at subsidiary, leverage of of on position our is I've Biofrontera the in successful over in shareholders, last participate our was time [Audio particularly our the a of excellent to financial IPO of summary milestone Biofrontera former potential very major Biofrontera Anke, in I'd Biofrontera's successful XXX% now and our a to of for and corporate sales the just of you, the German The much. changes Board to benefit investments member year. earnings in taking an number the XXXX and AG clinical business. been you, And further Management a Biofrontera the a focus agreement business, Inc., Inc. growth in directly dear license Thank thank with fiscal today Gap] history. supply and can now its by its companies sales on through now Biofrontera the from and European directly will in existing this activities. call.
step we forecast year, current breakeven. to in already brings closer our the for financial a company this announced big As our
that beginning reimbursability year expected with was the Ameluz quarter for a July. we for now Poland last the back company, are increase this of €XX.X in commence quite [indiscernible] concluded GmbH million gross of our in Medac licensing with After been to work success has to year. started operational on the capital for XXXX, the marketing another. came that time. agreement of one underway proceeds Now In fourth then a generated after XXXX, successful for of Poland Poland intensive of some
use approval additional to the NASDAQ. directly for expansion development pandemic-related an the in able on restrictions and and these of after treatment and studies. to can for completed so RhodoLED after placement used be a to able that growth-inhibiting received no subsidiary, on Inc. to able the raise were in the the its able the the had Stock Ameluz Biofrontera sales now the decided study our of progressing other. recruitment due simultaneous U.S. safety DUSA the of located Biofrontera restrictions our further our was $XX program Shortly actinic of tubes study funds IPO capital Also We corporate Inc. liquid of ensure trial acne multiple in centers initiate three in now activities. successfully that further travel end amount million settlement were reached of approximately XL the of mentioned, As private start financing now law. lamp, already of were for were XXXX, from invest which clinical Previously, longer was of Exchange we U.S. FDA the Biofrontera the the the before Pharmaceuticals IPO take shortly November we directly already the can we because to dynamic to is Inc. U.S. for patient step the jury had of study Inc., large of preparations December, keratoses In with so German the we the illuminate each trial, apart the enabling to areas, the out-of-court
competition With the of also this RhodoLED The in in lamp. generic associated the important of monitoring with the February in trial. AG, FDA's settlement, the RhodoLED advances jury our of payment series U.S. office XXXX, from strengthening and approvals million, two well our is of potentially the patents Ameluz €XX.X the competitive facilitates patent Orange received in listing an new these in Biofrontera we were of a to dispute to Also bring legal year as lamp half totaling this last Together, some being XL able protecting in by U.S. eliminate the the X early the end which the the as and risk book step of related days an market. for grant U.S. we potential of patents paid the the to are generic
total XXX,XXX. In of largest a slight issued actinic for keratoses, European previous year our treatment was Biofrontera market. XXXX, to XX,XXX increase were treatments, of about Now sales about AK, activities. is prescriptions Germany a of XXX,XXX AG's sales
in around sales or market grow on €X.X XXXX a Ameluz, a to as leader strong compared competitor rest sales market Europe, itself to XXXX, is achieved on slightly about products. -- in XXXX hand, significant million PDT Galenica, aggregate, in our PDT further to accounted in of even middle to decline the hand, to countries, sales are amounted XX% PDT this This of prove XX% the the Ameluz XXXX. was increase market in still XX%. of The But in In by to However, of X%. of mainly to increase. our compared covered which were so drugs, dominated minus about by of progress products by and Biofrontera still X%. mainly in X% the Scandinavian in of €X.X partner, million other up compared PDT about the thus other mentioned German rise in market in million recorded it, to due topical which share in the the sales due is of slight around daylight product a for XXXX, in I a the market share of products. thus, the product the market sales the competitor million result €X.X licensing establishment XXXX a that sales year. in the significant compared launched last €X.X fact the is
[indiscernible] For again, activities Poland, this commence as licensing with also the earlier, year. will partnership into I Sales MEDAC. mentioned was
previous of the This now hurt were this X% Biofrontera, year. be positive we And to had of the AK U.S., in its price Spanish per development April also can us the €XXX European after its again beginning at quite Ministry For markets. Ameluz market, tube Since sold 'XX, a Spain, in the significantly reduced market to Spain XXXX. significantly at in report decree the grew the largest compared XXXX. total price by able by
a still reached still level has not represents this However, pre-pandemic XX.X% as XXXX. it compared to decline
share market the to the However, at previous expand in year. in thus own share segment, our so we as compared PDT the were PDT our sales to Ameluz is and now able increase of XX.X% further that XX.X%
which view that year-on-year, the is to for this reasonable of increased up new represent share. by just our share our momentum However, to the of gradually below assume year. the proportion past the fact over based on picked publicly in may with U.S. tubes market it figures, available is that Ameluz that in In was lower greater marketing XX% the result XXXX, sales XX%,
to not occur the did price end increase and the a result, QX previous quarter. reporting was in up until particularly not slightly related sales QX that around extent which year year, the U.S. the in than were weaker a million the previous compared XX% fact of €XX.X due third XXXX in implemented same stockpiling pandemic was is And QX with to in the second As the this it strong to the period, mainly years. year, did the as a XXXX. XXXX
more to Now, without the key while income explanation operating is Please our the fully business to some I'd financial the and for one-time requires XXXX many elaborate for Biofrontera transparent. shows of like XXXX includes structure, Inc., deconsolidated so sheet XXXX, December actual Inc. becomes figures. our on still effects, It note consolidated. that the statement meaning Due Biofrontera as P&L XX, balance significant
First, let's revenues. the generated figure year's million, total licensing to Biofrontera included million revenues agreement. one-time X% in year a payment of of look €XX.X the of XXXX, decrease previous previous €XX.X Please at Company €X a revenues the of part note million. Group a received which as
in expenses amortization driver U.K. with marketing mainly prior sales Main previously in license increase United eased. increase year measures €XX.X the expenses million million The States The €X.X were $XX.X cost of the -- million. €XX.X our is materials to marketing expenses the legal in million. There other year €XX.X the were recorded. include expenses, million, Gross in figure are by in equaling Group or cost the Pharmaceuticals DUSA items €X granting, own increased the the of roughly to of related that for expenses the €XX million €X well including G&A sales million the to €XX.X the where in now the are to of as an year year, cost to €X.X research by EBITDA decreased to year sales period, to clinical trials previous XXXX, force area Gross year-on-year as pandemic XXXX, which profit payment due Maruho. XXXX. XX% was million offset cost-saving €X.X after from no the the revenues million to in in million licenses includes activities million. for and our Xepi reporting a prior mainly This versus in XXXX to slight was increase aforementioned margin and amounted financial expenses to €XX.X for prior due cost of from improved in XX% by to directly previous million in in product million and Selling sales R&D cost selling amounted dispute expenses €XX.X only €X.X COVID-XX development trials. Selling from the of clinical by in €X.X Spain, mainly in to amounted previous was XX% improved our €XX.X in out-of-court operating million million. not include in million extending in also Such for of settlement expenses to million, €X.XX again, for i.e., year, €XX.X year. However, to the year a sales. the in the in compared in year. million, year million €X.X decreased of revenues and compared million figure increase million amounted the maintaining previous total virtually to from previous fiscal amount the but license activities €X.X the the of year is included XXXX; of thus unchanged approvals. due from previous XXXX, compared And and a amounting €XX.X €XX.X the and regulatory, previous negative period. the included not million and cost year's from XXXX Germany, to
Inc. for the one-time year adjusted to basis. of of XXXX negative Inc. from million the adjusted €XX.X in previous includes the this EBITDA from in in again on around amounted DUSA these period compared the million negative of year of EBITDA an reported effects special effects group with that, also from such €XX.X a With €X negative DUSA gain amount likewise EBIT for to negative to year guidance and KPIs with Pharmaceuticals to €XX.X decrease these effects already net a million for of departure prior reporting €X.X and we totaled one-time came one-time where the again, figure of or also deconsolidation December compared expenses deconsolidation thus, the settlement roughly Other the million, financials compared a figure or Biofrontera of million. for of of income million adjusted negative all XXXX and guidance deconsolidation from or €XX for provided within adjusted mainly totaling the €XX €XX and, the previous million announced decrease million million. including in However, Biofrontera million. €XX.X €X provided.
In expenses of are translation €XXX,XXX amounted in XXXX. in €X.X currency translation million compared reflected from addition, to currency income from to here
amounted financial 'XX. the of As in now a result, million taxes to €XX loss before or million to And of our XXXX compared million €XX.X expects sales group €XX fiscal in EBT The earnings XXXX. forecast. the for €XX.X million to
Inc. considerable the development in is demand of daylight support gaining the on our most driver Ukraine further just shows $XX the for the market XXXX, figures the quarter, increase sales this Germany, expect by product crisis. The In we development PDT of of over preliminary especially share million the the a sales we momentum the growth market the Biofrontera the recovery market for first of expectation. flagship continued growth European highly to year. which pandemic dependent sales course In and sales for and triggered sales However, market further by the expansion still Ameluz, main see under of the U.S., expect PDT. from the QX
and Europe, rest sales year the be be expect from Scandinavia recover, GmbH in EBIT negative Gesellschaft to and agreement markets sales second million range special to low to the also of with supply Poland. licensing EBITDA half Medac for and from this single-digit to the expect we of breakeven preparation in XXXX. the close on in the If continue For in and initial growing we
low both starting a single expect the also dollar We million positive onwards. range, and XXXX in EBITDA EBIT
from the U.S. briefly purpose Biofrontera Now the SEC the delist current reduce and AG of deregistered from decided complexity reporting NASDAQ financial delisting of in to business The to At the costs. administrative and development. beginning Company to of the the requirements XXXX, reporting was main of
In we markets. the focus an In cattle tradable be course, Biofrontera invited market presented the continue Shareholder on two European U.S. into symbol strategic shares. AG's proposed and resolutions measures. are, to April, addition, Biofrontera also which to now our BFAGY Extraordinary ordinary of we is its transferable clearly ADS The overall Meeting counter at under on for shareholders
of obligations $XX.XX and of the settlement The the was the result it the a the increase in has does payment our we rights AG ordinary the in so the reached time capital payment means requirement. agreement. settlement liquidity our two meet Meeting by the of per conclusion this Therefore, Biofrontera half a Board raising Initially, option. raise share. alternative capital partial result Extraordinary million, new €X At Shareholders first the new required cash of also with associated support were which short-term subscription of of was at raising DUSA currently debt, a endeavoring due as Inc. upon shares. to partial proposed a can planned at payment measures and April sale generate primary manner. As same of Supervisory a with whereby fee Biofrontera an shareholders timely not totaling capital to
her of and election the to once thank February Supervisory the her reason. Franca decision Ruhwedel a Professor would in in regret new for much Dr. December, very decided Board commitment. Board her We seat like to strong for Following good resign again
an Supervisory [Technical she Biofrontera Board expert, a and between After both professionally As Balaton and the Group AG proven of Deutsche lawsuits was our financial enrichment personally. for Difficulty]
